Abstract
Gestational diabetes mellitus (GDM) is defined by maternal hyperglycemia, yet growing evidence indicates that it is a systemic disorder involving oxidative stress, inflammation, endothelial dysfunction and altered placental angiogenesis. The placenta plays a central role in translating maternal metabolic disturbances into fetal and vascular consequences. This narrative review aimed to synthesize current experimental and clinical evidence on the role of oxidative stress and inflammation in the regulation of placental angiogenesis in GDM. The reviewed studies consistently demonstrate that pregnancies complicated by GDM are characterized by increased oxidative stress and inflammatory activity at both systemic and placental levels. These disturbances are associated with endothelial dysfunction and dysregulation of angiogenic signaling, leading to abnormal placental vascular remodeling. Genetic susceptibility primarily influences maternal glucose metabolism, while placental oxidative and angiogenic alterations appear to develop downstream of metabolic stress and are further modulated by epigenetic mechanisms. Collectively, these processes contribute to the characteristic placental phenotype of GDM and may underlie fetal programming and long-term cardiometabolic risk in the offspring. Importantly, evidence from randomized trials and meta-analyses indicates that antioxidant-oriented interventions can partially improve redox balance, inflammatory status, and metabolic indices in women with GDM. Current evidence suggests that oxidative stress may represent a central link between maternal hyperglycemia and placental vascular dysfunction in GDM. Beyond glycemic control, targeting redox imbalance and inflammatory pathways may represent a potential complementary strategy to improve placental function and pregnancy outcomes. Integration of oxidative, inflammatory, and angiogenic biomarkers into future longitudinal studies may facilitate biological stratification of GDM and support the development of more personalized therapeutic approaches.
Keywords: Gestational diabetes mellitus, Oxidative stress, Inflammation, Angiogenesis, VEGF, Endothelial dysfunction, Placental angiogenesis, Pregnancy complications, Metabolic stress, Vascular remodeling
Introduction
Gestational diabetes mellitus (GDM), affecting approximately 5–20% of pregnancies worldwide is defined as glucose intolerance first recognized during pregnancy, represents one of the most prevalent metabolic disorders of gestation and remains a major contributor to maternal and fetal morbidity worldwide [1]. Its prevalence has increased steadily over recent decades, paralleling global rises in maternal age, obesity, and metabolic syndrome, making GDM a growing public health challenge [2]. Women with GDM are at increased risk of pregnancy complications, including hypertensive disorders, cesarean delivery, and future type 2 diabetes, while offspring face elevated risks of fetal overgrowth, perinatal morbidity, and long-term cardiometabolic disease [3]. While maternal hyperglycemia constitutes its diagnostic hallmark, GDM is increasingly recognized as a multifactorial disorder in which genetic predisposition, metabolic stress, oxidative imbalance, and chronic low-grade inflammation converge to impair placental structure and function [4]. The placenta is therefore not merely a passive target of maternal dysglycemia, but a central integrator of metabolic and vascular signals at the maternal–fetal interface.
A growing body of evidence indicates that oxidative stress plays a pivotal role in the pathophysiology of GDM. Excessive generation of reactive oxygen species (ROS), coupled with insufficient antioxidant defenses in placental and maternal tissues, leads to a sustained pro-oxidant state [5, 6]. Elevated levels of oxidative damage markers—including malondialdehyde (MDA), 8-hydroxy-2′-deoxyguanosine (8-OHdG), and increased xanthine oxidase activity—have been consistently documented in maternal circulation, placental tissue, and umbilical cord blood in GDM pregnancies [7–13]. Beyond causing molecular damage, excessive ROS activate redox-sensitive inflammatory pathways and disrupt signaling cascades essential for normal trophoblast function and vascular development. Physiological placental development depends on precisely coordinated angiogenesis, a process governed by angiogenic growth factors such as vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), which ensure adequate vascularization and efficient maternal–fetal exchange of oxygen and nutrients [14].
Histomorphological and molecular studies indicate that abnormalities in placental vascular structure and angiogenic signaling are observed in a substantial proportion of GDM pregnancies. Histopathological analyses consistently demonstrate features such as villous immaturity, increased capillary density (chorangiosis), stromal fibrosis, and syncytial knot formation in GDM placentas. In case–control histomorphological studies, these abnormalities have been reported in the majority of examined GDM placentas, with structural alterations observed in up to 60–80% of cases depending on study design and glycemic control [15–17].
Oxidative stress, chronic inflammation, and endothelial dysfunction collectively perturb angiogenic signaling, resulting in abnormal vascular remodeling, structurally immature microvessels, and impaired placental perfusion [18]. These vascular abnormalities are increasingly recognized as key contributors to placental dysfunction in GDM. Interindividual variability in the severity and clinical expression of GDM suggests an important modulatory role of genetic and epigenetic factors. Genetic susceptibility is largely driven by variants affecting glucose metabolism, insulin secretion, and insulin signaling, while genes involved in oxidative stress and inflammatory regulation may influence downstream placental responses [19]. In parallel, epigenetic mechanisms, including DNA methylation changes and dysregulated microRNA expression have emerged as critical regulators of β-cell function, immune signaling, endothelial homeostasis, and vascular remodeling in GDM [20]. These epigenetic modifications provide a mechanistic link between maternal metabolic stress and persistent alterations in placental and fetal gene regulation.
As a consequence of these converging processes, the placenta in GDM exhibits molecular signatures of oxidative damage, altered angiogenic factor expression, and impaired antioxidant capacity. These abnormalities compromise placental nutrient transport and vascular function and have been associated with adverse perinatal outcomes, including fetal macrosomia, intrauterine hypoxia, and long-term metabolic programming of the offspring [7, 21, 22].
Understanding how hyperglycemia-induced oxidative stress, inflammation, angiogenic dysregulation, and genetic and epigenetic modulation intersect at the placental level is essential for identifying predictive biomarkers and developing targeted interventions in GDM. Integrating these pathways provides a biologically informed framework for high-risk pregnancy complications and may facilitate novel strategies aimed at improving placental function and reducing long-term cardiometabolic risk in both mother and child. These processes likely begin prior to conception as part of maternal metabolic predisposition, but intensify during early and mid-pregnancy. Importantly, placental endocrine signaling may also influence maternal metabolic adaptation, suggesting bidirectional communication between the placenta and maternal β-cell function. This review focuses primarily on the maternal–placental interface, integrating systemic maternal metabolic and inflammatory disturbances with placental oxidative stress, endothelial dysfunction, and angiogenic remodeling. Although the placenta is the central biological focus, extra-placental maternal tissues contribute substantially to the biochemical environment in which placental dysfunction develops.
Materials and methods
This article constitutes a narrative review of the literature aimed at synthesizing current knowledge on the interplay between oxidative stress, inflammation, angiogenesis, and genetic and epigenetic regulation in GDM. Literature screening and study selection were performed independently by two reviewers (A.B. and M.K.) to enhance methodological rigor. The final selection and consistency of included studies were verified by a senior author (M.Sz). Any discrepancies in study selection were resolved through discussion and consensus between the reviewers, and when necessary, adjudicated by a senior author (M.Sz).
The review was conducted through a comprehensive search of the PubMed, Scopus, and Web of Science databases for articles published primarily between 2000 and 2025. Although the literature search followed PRISMA principles for transparency, this review was not designed as a formal systematic review and therefore does not include quantitative synthesis or risk-of-bias assessment [23–25] (Fig. 1).
Fig. 1.

PRISMA 2020 flow diagram of the literature search and study selection process [26] Records were removed for other reasons (n = 93), including articles not related to pregnancy or placental biology, studies focused on diabetes outside gestation, papers lacking data on oxidative stress, inflammation, or angiogenesis, non-relevant experimental models, and publication types not suitable for synthesis (editorials, commentaries, conference abstracts, or case reports)
Search terms included combinations of: gestational diabetes mellitus, oxidative stress, reactive oxygen species, inflammation, angiogenesis, placenta, VEGF, endothelial dysfunction, epigenetics, DNA methylation, microRNA, and genetics. Additional references were identified by manual screening of bibliographies from key articles and recent reviews.
Both experimental and clinical studies were considered, including observational studies, randomized controlled trials, meta-analyses, and mechanistic investigations using placental tissue or cellular models. Priority was given to high-quality human studies and recent publications that provided mechanistic insight into placental biology in GDM. Grey literature, including conference abstracts, preprints, and non-peer-reviewed reports, was not systematically included. The review focused on peer-reviewed publications to ensure the reliability and scientific quality of the evidence. Given the narrative nature of this review, no formal risk-of-bias assessment was performed, as the primary aim was to provide a mechanistic and integrative overview rather than a quantitative synthesis of evidence.
The aim of this narrative approach was not to perform a quantitative synthesis, but to integrate molecular, genetic, epigenetic, and clinical evidence into a coherent conceptual framework describing how maternal hyperglycemia is transduced into oxidative stress, inflammatory activation, and angiogenic dysregulation at the maternal–fetal interface.
Diagnosis
Current international clinical practice is largely guided by recommendations issued by the International Association of Diabetes and Pregnancy Study Groups (IADPSG), derived from the findings of the HAPO study. These guidelines advocate universal screening between 24 and 28 weeks of gestation using a 75-g, 2-hour oral glucose tolerance test, with gestational diabetes diagnosed when any of the following thresholds are met: fasting plasma glucose ≥ 92 mg/dL, 1-hour glucose ≥ 180 mg/dL, or 2-hour glucose ≥ 153 mg/dL [27, 28]. In Poland, national standards evolved from the PTD 2011 protocol to criteria aligned with the WHO 2013 and IADPSG recommendations, which were formally implemented in 2014 [29, 30]. Although HbA1c and fasting glucose measurements in early pregnancy may help detect previously unrecognized overt diabetes, they are not sufficiently sensitive to serve as standalone diagnostic tools for GDM. Postpartum re-evaluation, typically 4–12 weeks after delivery using a 75-g OGTT, is recommended to distinguish transient gestational dysglycemia from persistent abnormalities in glucose metabolism and to identify women at high risk for future type 2 diabetes. Accurate and timely diagnosis is essential for implementing appropriate therapeutic interventions and for reducing both short- and long-term metabolic consequences for the mother and offspring (“2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022,” 2022; [31, 32]).
Genetic background
The majority of available data refer to maternal genotype, whereas fetal genetic contribution and placental-specific variation remain less well characterized. These findings are primarily derived from maternal genotype studies conducted in multi-ethnic and case–control pregnancy cohorts. Nunes et al., synthesized data from large genome-wide maternal germline variants association studies and demonstrated that the strongest and most reproducible genetic signals in GDM map to loci regulating insulin secretion and glucose homeostasis, particularly Transcription Factor 7 Like 2 (TCF7L2), Melatonin Receptor 1B (MTNR1B), CDK5 Regulatory Subunit Associated Protein 1-Like 1 (CDKAL1), Insulin Receptor Substrate 1 (IRS1). Their review, based on multi-ethnic cohorts comprising tens of thousands of pregnancies, showed that these variants primarily affect β-cell function and adaptive insulin secretion rather than pathways directly related to oxidative stress or angiogenesis. This study established the concept that the genetic core of GDM is metabolic in nature and that placental pathology develops downstream of this inherited metabolic vulnerability [19]. In the following study, using case–control cohorts of pregnant women, Papadopoulou et al., and Hassan et al., genotyped common polymorphisms in TCF7L2 and MTNR1B and correlated them with glycemic traits and GDM risk. They demonstrated that the TCF7L2 rs7903146 and MTNR1B rs10830963 variants are associated with elevated fasting glucose and impaired early insulin secretion during pregnancy. These findings indicate that genetically limited β-cell reserve constrains the maternal capacity to compensate for gestational insulin resistance, thereby initiating the hyperglycemic milieu that drives placental oxidative stress and inflammation [33, 34]. Extending this preliminary study, Rosta et al., analyzed polymorphisms in CDKAL1 and IRS1 in women with and without GDM and showed that risk alleles in these genes impair proinsulin processing and insulin signaling, respectively. The CDKAL1 rs7754840 polymorphism was significantly associated with GDM under the codominant homozygous model. Carriers of the CC genotype showed an increased risk of GDM compared with GG carriers (OR = 1.748; 95% CI: 1.178–2.593; P = 0.006), which remained significant after adjustment (OR = 1.715; 95% CI: 1.133–2.595; P = 0.011). No significant associations were observed for CDKAL1 rs7756992 under any genetic model. Age-stratified analysis indicated that individuals < 30 years with the rs7754840 CC genotype had higher fasting and postprandial glucose levels than GG carriers (P < 0.05). Their genetic association data confirmed that inherited defects in both insulin synthesis and peripheral insulin action contribute to disease susceptibility, reinforcing the notion that metabolic stress precedes and conditions placental pathology [33, 34]. Importantly, these genetic association studies do not directly implicate placental pathways but instead define a metabolic predisposition that acts upstream of placental dysfunction. This raises the question of how inherited defects in insulin secretion and signaling are translated into oxidative, inflammatory, and adaptive responses at the placental level.
Moving from inherited metabolic susceptibility to placental molecular responses, Diceglie et al., investigated placental tissue obtained from normoweight women and from obese pregnancies with and without GDM, quantifying the expression of antioxidant and autophagy-related genes using quantitative PCR–based approaches. They demonstrated that the expression of key antioxidant genes, including catalase (CAT), glutathione peroxidase 1 (GPX1), and glutathione synthetase (GSS), was significantly reduced in placentas from obese compared with normoweight controls, indicating early impairment of placental redox defense under metabolic stress. In parallel, the pro-autophagic gene unc-51-like autophagy activating kinase 1 (ULK1) was upregulated, whereas expression of PH domain and leucine-rich repeat protein phosphatase 1 (PHLPP1), a regulator of chaperone-mediated autophagy, was decreased, suggesting activation of compensatory autophagic pathways in response to oxidative and metabolic burden. Notably, PHLPP1 expression was increased in obese GDM placentas relative to obese non-GDM cases, indicating disease-specific remodeling of autophagy-related signaling following the onset of dysglycemia. When stratified by fetal sex, these alterations exhibited pronounced sexual dimorphism, affecting both antioxidant and chaperone-mediated autophagy–related gene expression. Together, these findings indicate that placental redox homeostasis in metabolically compromised pregnancies is shaped not only by hyperglycemia but also by obesity, fetal sex, and adaptive autophagic responses. The transcriptional downregulation of antioxidant defenses coupled with dysregulated autophagy provides a molecular framework explaining the heightened susceptibility of GDM placentas to oxidative injury and identifies placental autophagy as a potential therapeutic target in metabolic pregnancy disorders [35]. Nevertheless, these alterations may be primarily driven by maternal obesity, indicating that redox imbalance precedes overt dysglycemia and may sensitize the placenta to subsequent GDM-related injury.
While altered redox balance and autophagic remodeling define early placental responses to metabolic stress, these processes are tightly coupled to inflammatory signaling pathways that directly regulate placental angiogenesis. Genetic variation affecting cytokine production therefore represents a critical interface through which metabolic and oxidative stress may be translated into vascular dysfunction. At the interface between inflammation and angiogenic regulation, Halvatsiotis et al., focused on a defined promoter polymorphism in the interleukin-6 gene (IL6), namely the − 174 G/C variant (rs1800795). This single-nucleotide polymorphism is located upstream of the IL6 transcription start site and directly influences cytokine transcriptional activity. The authors demonstrated that carriage of the G allele (GG or GC genotypes) was associated with a significantly increased risk of both GDM and preeclampsia in obese pregnant women, identifying rs1800795 as a concrete inflammatory risk variant in these pregnancy complications. In parallel, placental tissue transcriptional profiling revealed marked alterations in the angiogenic pathway. In obese women with GDM or preeclampsia, vascular endothelial growth factor (VEGF) mRNA levels were significantly reduced, while expression of VEGF receptors (VEGFRs) was increased, indicating a dissociation between ligand availability and receptor abundance within the placental angiogenic axis. When interpreted together with the genetic data, these findings suggest that the pro-inflammatory IL6 rs1800795 G allele establishes a background of heightened inflammatory signaling that reshapes placental angiogenic programming. Specifically, genetically driven upregulation of IL-6–mediated inflammation appears to suppress VEGF expression while inducing compensatory upregulation of its receptors, reflecting maladaptive vascular signaling. Collectively, this combined genetic (IL6 rs1800795) and transcriptional (VEGF/VEGFR) evidence demonstrates how inherited variation in cytokine regulation modulates the placental response to metabolic stress in obesity, predisposing to endothelial dysfunction, abnormal vascular remodeling, and the development of GDM and preeclampsia [36]. Beyond inflammatory regulation of angiogenesis, several studies have addressed whether inherited variation within core angiogenic genes directly modifies GDM susceptibility and vascular signaling, independently of upstream inflammatory cues. Genetic modulation of angiogenesis has been addressed in both association and tissue-based studies. Dong et al., performed a large case–control study including 239 women with GDM and 275 normoglycemic pregnant controls to investigate whether genetic variation within VEGF and circulating VEGF levels are associated with GDM risk. Using TaqMan-based genotyping, they analyzed five VEGF polymorphisms (rs2146323, rs2010963, rs3025039, rs3025010, and rs833069), while serum VEGF concentrations were quantified by ELISA. Haplotype structure was reconstructed with SHEsis software to capture combined genetic effects. They demonstrated that carriers of the rs2146323 A allele (AA and CA + AA genotypes) and the rs3025039 T allele (CT, TT, and CT + TT genotypes) exhibited a significantly increased risk of GDM. In contrast, rs2010963, rs3025010, and rs833069 showed no independent association. Haplotype analysis further revealed that specific VEGF haplotypes (CAAC, CAAT, CACC, CACT, GACT, GGCT) differed significantly between GDM and control groups, indicating that combinatorial genetic architecture within the VEGF locus modulates disease susceptibility. Importantly, women carrying the rs3025039 CT + TT genotypes displayed higher circulating VEGF levels than CC carriers, directly linking genetic variation to functional changes in angiogenic signaling. Multivariate modeling identified rs2146323 CA + AA, rs3025039 CT + TT, and elevated VEGF expression as independent risk factors for GDM, alongside classical metabolic predictors (age, family history of diabetes, prior GDM, BMI, fasting glucose, insulin, and HOMA-IR), whereas preserved β-cell function (HOMA-β) was protective. This integrated genetic–phenotypic approach demonstrates that inherited variation within VEGF not only predisposes to GDM but also shapes systemic angiogenic tone. The study provides direct evidence that angiogenic gene polymorphisms translate into altered VEGF expression, thereby linking genetic susceptibility with vascular and metabolic dysregulation characteristic of GDM [37].
Although VEGF polymorphisms and circulating VEGF levels define genetic and systemic angiogenic tone, they do not explain how altered signaling is executed within placental endothelial cells. This mechanistic gap has been addressed by studies dissecting VEGF receptor expression and downstream signaling in GDM placentas. Troncoso et al., addressed the paradox of placental hypervascularization in GDM by dissecting VEGF receptor signaling at both the tissue and cellular levels. Using placental tissue samples from women with normal pregnancies and those with GDM, they quantified endothelial markers (CD31, CD34), VEGF, VEGFR1 (Flt-1), VEGFR2 (KDR), and the phosphorylation status of KDR at tyrosine residues Y951 and Y1175 by molecular and immunohistochemical methods. GDM placentas exhibited significantly higher CD31 and CD34 protein levels, indicating an increased endothelial cell mass, and histological analysis revealed a higher number of placental vessels with reduced luminal area, consistent with hypervascularization composed of immature microvessels. At the molecular level, Flt-1 expression was reduced at both mRNA and protein levels in GDM placentas, whereas KDR mRNA was decreased but KDR protein abundance was increased. Despite unchanged phosphorylation at Y951 and Y1175 in whole placental homogenates, this receptor profile reflected a shift toward a pro-migratory, pro-angiogenic endothelial phenotype. Functional assays in human umbilical vein endothelial cells (HUVECs) demonstrated that GDM did not enhance endothelial proliferation but significantly increased migratory capacity. Moreover, conditioned medium derived from GDM HUVEC cultures increased KDR protein expression, tube formation, and migration in endothelial cells from normoglycemic pregnancies. Therefore, integrated tissue-based and functional experiments show that GDM is characterized by reduced expression of the anti-angiogenic decoy receptor Flt-1 and a relative dominance of KDR-mediated signaling. This receptor-level imbalance promotes endothelial activation and migration rather than coordinated vessel maturation, providing a mechanistic explanation for placental hypervascularization with structurally abnormal microvessels. The study of Troncoso et al., thus establishes a direct link between altered VEGF receptor signaling and the aberrant vascular architecture characteristic of the GDM placenta in vitro [38]. This pattern explains how GDM placentas can exhibit increased vascular density yet impaired perfusion efficiency, providing a mechanistic basis for fetal hypoxia despite apparent hypervascularization.
These studies delineate a hierarchical model in which the primary genetic architecture of GDM is rooted in metabolic regulation, while inherited variation in inflammatory, antioxidant, and angiogenic pathways modulates how maternal hyperglycemia and obesity are translated into placental oxidative stress, endothelial dysfunction, and abnormal vascular remodeling (Fig. 2). Importantly, these loci predominantly affect maternal glucose metabolism and insulin dynamics, rather than placental oxidative or angiogenic pathways, positioning placental dysfunction as a downstream consequence of inherited metabolic stress.
Fig. 2.

Genetic and molecular pathways linking maternal metabolism with placental pathology in GDM. GDM – gestational diabetes mellitus; GWAS – genome-wide association study; TCF7L2 – transcription factor 7-like 2; MTNR1B – melatonin receptor 1B; CDKAL1 – CDK5 regulatory subunit associated protein 1-like 1; IRS1 – insulin receptor substrate 1; CAT – catalase; GPX1 – glutathione peroxidase 1; GSS – glutathione synthetase; ULK1 – unc-51-like autophagy activating kinase 1; PHLPP1 – PH domain leucine-rich repeat protein phosphatase 1; IL6 – interleukin 6; VEGF – vascular endothelial growth factor; FLT1 (VEGFR1) – fms-like tyrosine kinase 1, vascular endothelial growth factor receptor 1; KDR (VEGFR2) – kinase insert domain receptor, vascular endothelial growth factor receptor 2
Epigenetic regulation in GDM
Recent epigenetic studies in maternal plasma, placental tissue, and cord blood indicate that microRNAs (miRNAs) represent a central regulatory layer linking maternal hyperglycemia with oxidative stress, inflammation, and placental dysfunction in GDM. In a prospective cohort study, Wander et al., profiled circulating miRNAs in early and mid-pregnancy and demonstrated that altered levels of miR-21, miR-155, miR-210, and miR-29a precede the clinical diagnosis of GDM. Using quantitative PCR–based assays in maternal plasma, they showed that these miRNAs are associated with fasting glucose levels, insulin resistance, and subsequent GDM risk, providing direct evidence that epigenetic dysregulation emerges early in pregnancy and reflects underlying metabolic stress [39]. Complementing these findings, Trejo-González et al., synthesized data from multiple placental and circulating miRNA studies and demonstrated that miR-21, miR-126, miR-146a, miR-155, miR-210, and miR-29a are consistently dysregulated in GDM. Their review linked these miRNAs to pathways governing insulin signaling, endothelial function, redox balance, and angiogenesis, establishing that miRNA networks extend maternal metabolic disturbance into inflammatory and vascular domains within the placenta [40]. Although these findings provide important longitudinal insight, prospective cohort data integrating oxidative stress, inflammation, and angiogenesis simultaneously remain limited. Some of these epigenetic changes may overlap with physiological adaptations of early pregnancy, making it challenging to distinguish disease-specific alterations from normal gestational remodeling.
Beyond post-transcriptional regulation, DNA methylation constitutes a second major epigenetic axis in GDM. Canouil et al., explored the association between GDM exposure and DNA methylation in maternal blood and newborn cord blood in 536 mother-offspring pairs from the prospective FinnGeDi cohort using Illumina MethylationEPIC 850 K BeadChip arrays. The study identified differential methylation in placental genes directly involved in glucose transport and vascular regulation, including SLC2A1 (GLUT1), LEP, ADIPOQ, HIF1A, and VEGFA. For example, altered methylation of the SLC2A1 promoter in GDM placentas correlates with increased glucose transfer capacity, linking epigenetic remodeling to functional nutrient flux at the maternal–fetal interface [41]. Using genome-wide methylation arrays in placental tissue, Reichetzeder et al., demonstrated significantly increased global DNA methylation in GDM placentas, indicating a broad epigenomic response to the diabetic intrauterine environment [42]. In a high-resolution epigenome-wide association study, Chen et al., identified hundreds of differentially methylated CpG sites in GDM placentas, particularly within genes related to insulin signaling, oxidative stress responses, mitochondrial metabolism, and vascular development. These methylation changes were accompanied by altered gene expression, showing that maternal hyperglycemia reshapes placental transcriptional programs through epigenetic mechanisms [43].
Extending these observations, Lu et al., performed integrated methylome and transcriptome analyses in placental tissue and umbilical cord blood. Using parallel DNA methylation profiling and RNA sequencing, they demonstrated coordinated epigenetic and transcriptional alterations in pathways related to glucose metabolism, inflammation, and angiogenesis in GDM pregnancies [44]. Similarly, Awamleh et al., analyzed placental and cord blood DNA using genome-wide methylation platforms and identified hundreds of CpG sites modified by in utero exposure to GDM. Several of these marks persisted beyond birth and were associated with metabolic traits in the offspring, providing mechanistic evidence for fetal programming [45]. In an earlier study, Rong et al., had already shown that placental DNA methylation patterns differ significantly between GDM and normoglycemic pregnancies, linking epigenomic remodeling to altered fetal growth trajectories [46].
Environmental modifiers further interact with this epigenetic landscape. Human placental studies by Lesseur et al., and Nogues et al., demonstrated that maternal obesity and metabolic stress are associated with altered DNA methylation of key placental genes, including those regulating adipokine and metabolic signaling, indicating that the placental epigenome directly responds to an adverse intrauterine environment [47, 48]. Complementing these observations, Basak et al., showed that maternal nutritional status at conception, particularly folate availability, modulates DNA methylation of metastable epialleles in the offspring, establishing a mechanistic link between one-carbon metabolism, S-adenosylmethionine synthesis, and epigenomic patterning [49]. Unlike genetic variants, epigenetic marks remain at least partially reversible. Experimental and clinical data indicate that nutritional modulation, redox balance, and metabolic control can reshape DNA methylation and miRNA profiles, positioning the placental epigenome as a dynamic therapeutic target rather than a passive biomarker of disease [49].
Placental mitochondrial dysfunction may constitute a key upstream source of ROS in GDM, linking metabolic stress to redox-sensitive pathways such as NF-κB and Nrf2. These pathways may in turn modulate endothelial activation, stromal signaling, antioxidant defense, and epigenetic remodeling, thereby influencing placental angiogenesis. Compartment-specific placental inflammatory remodeling has also been demonstrated in women with obesity and/or GDM, including altered TNFα staining in syncytiotrophoblast and reduced IL-6 staining in villous stroma and fetal vessels [50].
Oxidative stress and angiogenesis in GDM patients
Madazli et al., investigated oxidative stress in pregnancies complicated by GDM using biochemical assays in maternal and cord plasma. They demonstrated significantly higher concentrations of malondialdehyde (MDA), a stable end product of lipid peroxidation, compared with normoglycemic pregnancies. These findings provide evidence of increased systemic oxidative stress in GDM. Consistent with these findings, placental studies have also shown increased oxidative damage in placental tissue [22]. Moreover, Lappas et al., investigated placental function using ex vivo explant cultures obtained from women with gestational diabetes mellitus and normoglycemic controls. By combining immunoassays for cytokines with biochemical detection of 8-isoprostanes as markers of lipid peroxidation, they demonstrated that placental tissue from GDM pregnancies releases significantly higher amounts of IL-6, TNF-α, and oxidative stress products. This experimental design directly established the placenta as an active source of both reactive oxygen species and inflammatory mediators in GDM, rather than a passive target of systemic metabolic disturbances. The findings indicate that oxidative stress and inflammation are locally generated within the maternal–fetal interface and coexist in a tightly coupled manner [51]. In a subsequent study, Saucedo et al., synthesized experimental and clinical evidence to clarify the molecular mechanisms linking these processes. Their analysis showed that excessive ROS activate redox-sensitive transcription factors, particularly NF-κB, which in turn upregulates the transcription of IL-6, TNF-α, and other pro-inflammatory genes. This creates a self-perpetuating loop in which oxidative stress amplifies inflammation and inflammation further enhances ROS generation. In the placental context, such signaling disrupts endothelial homeostasis, promotes a pro-inflammatory vascular phenotype, and predisposes to endothelial dysfunction, as an early determinant of abnormal placental vascular development [52]. At the level of angiogenic signaling, Meng et al., examined placental tissue samples using quantitative RT-PCR and immunoblotting to assess VEGF-A and VEGFR2 expression. They reported significantly altered mRNA and protein levels in GDM placentas, demonstrating that canonical VEGF-dependent angiogenic pathways are disturbed in this condition. These molecular changes observed in placental tissue indicate that endothelial growth and vessel patterning are regulated in an abnormal biochemical environment [53]. Extending these observations, Troncoso et al., applied immunohistochemistry and functional assays in isolated fetoplacental endothelial cells in vitro to characterize receptor-level signaling. They demonstrated a shift toward enhanced activation of the pro-angiogenic receptor VEGFR2 accompanied by reduced expression of the anti-angiogenic receptor Flt-1. This imbalance favors endothelial migration and activation without coordinated vessel maturation, providing a mechanistic basis for the structurally abnormal vasculature observed in GDM placentas [38]. The functional consequences of hyperglycemia on endothelial behavior were directly tested by Zhou et al., who exposed in vitro fetoplacental endothelial cells to elevated glucose concentrations and assessed proliferation, migration, and tube formation. Using standardized in vitro angiogenesis assays, they showed that hyperglycemia blunts endothelial responsiveness, particularly to FGF2 stimulation, confirming that the angiogenic machinery itself is intrinsically compromised in fetoplacental endothelial cells in vitro in the diabetic intrauterine environment [54]. Recently, Klid et al., combined placental metabolomic profiling with molecular and cellular approaches to identify the succinate–SUCNR1 axis as a novel regulator of placental angiogenesis in GDM. They demonstrated increased succinate levels in placental tissue samples and upregulated SUCNR1 expression and showed that activation of this pathway and showed that activation of this pathway stimulates endothelial proliferation, migration, and tube formation. These experiments provide a metabolic mechanism explaining the hypervascularization frequently observed in GDM placentas and link altered intermediary metabolism directly to vascular remodeling [55] (Table 1).
Table 1.
Key studies describing oxidative stress, inflammation, and angiogenic dysregulation in the GDM placenta
| Author | Study material / model | Methods | Key findings | Biological implication |
|---|---|---|---|---|
| Lappas et al., [51] | Placental explants, adipose and skeletal muscle tissue from GDM and control pregnancies | Ex vivo tissue cultures; ELISA for IL-6 and TNF-α; biochemical detection of 8-isoprostanes | Tissues from GDM pregnancies released significantly higher amounts of pro-inflammatory cytokines and oxidative stress markers | The placenta in GDM is an active source of ROS and inflammation; oxidative stress and inflammation are generated locally at the maternal–fetal interface |
| Saucedo et al., [52] | Review of clinical and experimental studies | Pathway and mechanistic synthesis | Excess ROS activate NF-κB, increasing IL-6 and TNF-α and creating a ROS–inflammation feedback loop | Provides a mechanistic preliminary study linking oxidative stress to chronic placental inflammation and endothelial dysfunction |
| Meng et al., [56] | Placental tissue from GDM and controls | RT-PCR, Western blotting | Altered expression of VEGF-A and VEGFR2 in GDM placentas | Canonical VEGF-dependent angiogenic pathways are disrupted in GDM |
| Troncoso et al., [38] | Fetoplacental endothelial cells and placental tissue | Immunohistochemistry; functional endothelial assays | Increased pro-angiogenic VEGFR2 activation with reduced anti-angiogenic Flt-1 | Imbalance between pro- and anti-angiogenic signaling favors aberrant vascular activation |
| Zhou et al., [54] | Fetoplacental endothelial cells in vitro | Proliferation, migration, and tube-formation assays | Hyperglycemia blunts endothelial responses, particularly to FGF2 | Angiogenic capacity is functionally impaired in a hyperglycemic environment |
| Klid et al., [55] | GDM placentas and endothelial models | Metabolomics; expression analyses; angiogenesis assays | Elevated placental succinate and SUCNR1; pathway activation stimulates endothelial proliferation and migration | Identifies a metabolic driver of placental hypervascularization in GDM |
GDM gestational diabetes mellitus, ROS reactive oxygen species, NF-κB nuclear factor kappa B, IL-6 interleukin 6, TNF-α tumor necrosis factor alpha, VEGF vascular endothelial growth factor, FLT1 (VEGFR1) fms-like tyrosine kinase 1, vascular endothelial growth factor receptor 1, KDR (VEGFR2) kinase insert domain receptor, vascular endothelial growth factor receptor 2, FGF2 fibroblast growth factor 2, HUVEC human umbilical vein endothelial cells
Collectively, these studies, employing complementary biochemical, molecular, and functional methodologies, define a coherent pathogenic cascade in which locally generated oxidative stress and inflammation converge on endothelial dysfunction and angiogenic imbalance. Importantly, placental angiogenesis in GDM is not driven by VEGF signaling alone but reflects a complex interplay of metabolic, inflammatory, and hypoxic stimuli. Maternal hyperglycemia, oxidative stress, and altered metabolic signaling collectively reshape the placental microenvironment, influencing angiogenic pathways beyond classical VEGF-mediated mechanisms. In this context, angiogenic alterations may represent both maladaptive and compensatory responses to impaired oxygen and nutrient delivery. These changes are closely linked to clinically relevant outcomes, including fetal macrosomia, relative placental hypoxia, and abnormal placental growth patterns. The resulting phenotype, characterized by increased vascular density with structurally immature vessels, may contribute to inefficient perfusion and increased susceptibility to adverse perinatal outcomes. Through ROS-driven NF-κB signaling, altered growth-factor pathways, and metabolite-mediated receptor activation, the GDM placenta is remodeled into a structurally and functionally abnormal vascular organ (Fig. 3). These disturbances have important clinical implications, as summarized in Table 2 (Table 2). Importantly, the observed alterations in placental angiogenesis in GDM should not be interpreted as purely pathological. Emerging evidence also suggests that these changes may reflect a combination of maladaptive and compensatory mechanisms aimed at maintaining adequate placental perfusion in the context of metabolic and oxidative stress. Distinguishing between causal and adaptive angiogenic responses remains challenging, as most available data are derived from cross-sectional and experimental studies. Longitudinal and functional investigations are required to determine whether altered angiogenic signaling represents a primary driver of placental dysfunction or a secondary adaptive response to an adverse intrauterine environment. In this context, placental hypervascularization observed in GDM may represent an adaptive response to relative hypoxia, although its structural immaturity suggests incomplete or dysregulated compensation.
Fig. 3.

Integrated model of oxidative, inflammatory, and angiogenic dysregulation in the placenta in GDM. GDM – gestational diabetes mellitus; ROS – reactive oxygen species; NF-κB – nuclear factor kappa B; IL-6 – interleukin 6; TNF-α – tumor necrosis factor alpha; MDA – malondialdehyde; VEGF – vascular endothelial growth factor; FLT1 (VEGFR1) – fms-like tyrosine kinase 1, vascular endothelial growth factor receptor 1; KDR (VEGFR2) – kinase insert domain receptor, vascular endothelial growth factor receptor 2; FGF2 – fibroblast growth factor 2; SUCNR1 – succinate receptor 1; HUVEC – human umbilical vein endothelial cells
Table 2.
Biomarkers with translational potential
| Biomarker | Compartment | Clinical relevance |
|---|---|---|
| MDA / 8-isoprostanes | Maternal plasma, placenta | Indicator of oxidative burden; correlates with placental dysfunction |
| 8-OHdG | Urine, placenta | Oxidative DNA damage; early predictor of GDM |
| VEGF / sFlt-1 | Maternal plasma, placenta | Angiogenic imbalance; reflects vascular remodeling |
| Succinate | Placenta | Metabolic driver of hyperangiogenesis |
| IL-6, TNF-α | Maternal plasma, placenta | Inflammatory tone; links OS to endothelial dysfunction |
GDM gestational diabetes mellitus, MDA malondialdehyde, 8-OHdG 8-hydroxy-2′-deoxyguanosine, XO xanthine oxidase, VEGF vascular endothelial growth factor, sFlt-1 soluble fms-like tyrosine kinase-1, PGF placental growth factor, CAT catalase, GPX1 glutathione peroxidase 1, SOD2 superoxide dismutase 2, IL-6 interleukin 6, TNF-α tumor necrosis factor alpha
Beyond the placenta itself, systemic maternal tissues including adipose tissue, liver, skeletal muscle, and pancreatic β-cells contribute to the metabolic and inflammatory environment of GDM. Adipose-derived cytokines, hepatic insulin resistance, altered skeletal muscle glucose utilization, and insufficient β-cell compensation collectively enhance oxidative stress and inflammatory signaling, thereby shaping placental phenotype and angiogenic adaptation at the maternal–placental interface (Table 3).
Table 3.
Genetic determinants linking maternal metabolism with placental oxidative stress and angiogenic dysregulation in GDM
| Author (year) | Study design / population | Genes / variants analyzed | Methods | Key findings |
|---|---|---|---|---|
| Brito Nunes et al., [19] | Review of multi-ethnic GWAS (tens of thousands of pregnancies) | TCF7L2, MTNR1B, CDKAL1, IRS1 | Meta-analysis of GWAS datasets | The strongest and most reproducible genetic signals in GDM map to loci regulating insulin secretion and glucose homeostasis |
| Hassan et al., [33], Papadopoulou, [34] | Case–control cohorts of pregnant women | TCF7L2 rs7903146; MTNR1B rs10830963 | Genotyping; glycemic phenotyping | Risk alleles associate with higher fasting glucose and impaired early insulin secretion |
| Rosta et al., | Case–control cohorts | CDKAL1, IRS1 polymorphisms | Genotyping | Risk alleles impair proinsulin processing and insulin signaling |
| Diceglie et al., [35] | Placental tissue from normoweight and obese pregnancies ± GDM | CAT, GPX1, GSS, ULK1, PHLPP1 | qPCR-based expression profiling | Antioxidant genes downregulated; ULK1 upregulated; PHLPP1 decreased in obesity, increased in obese GDM; sexual dimorphism |
| Halvatsiotis et al., [36] | Obese pregnancies with/without GDM, T2D, preeclampsia | IL6 promoter polymorphisms; VEGF, VEGF receptors | Genotyping; placental gene expression | IL6 G allele increases GDM/PE risk; VEGF ↓ and VEGF receptors ↑ in complicated pregnancies |
| Dong et al., 2019 | Case–control (239 GDM, 275 controls) | VEGF rs2146323, rs3025039, rs2010963, rs3025010, rs833069 | TaqMan genotyping; ELISA; haplotype analysis | rs2146323 A and rs3025039 T increase GDM risk; rs3025039 CT + TT → higher VEGF levels |
| Troncoso et al., [38] | Placental tissue and HUVEC functional assays | FLT1, KDR (VEGFR1/2) | IHC, qPCR, Western blot; migration and tube-formation assays | Flt-1 ↓, KDR protein ↑; enhanced endothelial migration; immature hypervascularization |
GDM gestational diabetes mellitus, GWAS genome-wide association study, T2D type 2 diabetes, PE preeclampsia, qPCR quantitative polymerase chain reaction, ELISA enzyme-linked immunosorbent assay, IHC immunohistochemistry, HUVEC human umbilical vein endothelial cells, TCF7L2 transcription factor 7-like 2, MTNR1B melatonin receptor 1B, CDKAL1 CDK5 regulatory subunit associated protein 1-like 1, IRS1 insulin receptor substrate 1, CAT catalase, GPX1 glutathione peroxidase 1, GSS glutathione synthetase, ULK1 unc-51-like autophagy activating kinase 1, PHLPP1 PH domain leucine-rich repeat protein phosphatase 1, IL6 interleukin 6, VEGF vascular endothelial growth factor, FLT1 (VEGFR1) fms-like tyrosine kinase 1, vascular endothelial growth factor receptor 1, KDR (VEGFR2) kinase insert domain receptor, vascular endothelial growth factor receptor 2
Ferroptosis
Ferroptosis is a regulated form of cell death characterized by iron-dependent lipid peroxidation and failure of antioxidant defense systems [57, 58]. Unlike apoptosis or necrosis, ferroptosis is driven by the accumulation of oxidized phospholipids in cellular membranes, resulting from an imbalance between ROS production and lipid peroxide detoxification [59]. A central role in this process is played by glutathione peroxidase 4 (GPX4), which protects cells from lipid peroxidation by reducing phospholipid hydroperoxides. Impairment of GPX4 activity, depletion of GSH, or disruption of cystine uptake via the system Xc⁻ (SLC7A11 transporter) promotes ferroptotic cell death. In the context of GDM, chronic hyperglycemia induces excessive ROS generation, mitochondrial dysfunction, and enhanced lipid peroxidation, creating a biochemical environment favorable for ferroptosis activation [60, 61]. Elevated intracellular iron levels, frequently observed in metabolically stressed tissues, further amplify oxidative damage through Fenton chemistry, accelerating lipid radical formation. In trophoblast cells, these processes may disrupt membrane integrity, impair cellular viability, and alter placental development [59, 60]. Importantly, ferroptosis provides a mechanistic link between oxidative stress and placental dysfunction in GDM. Ferroptotic injury in trophoblasts may compromise syncytiotrophoblast integrity, disrupt nutrient transport, and impair endocrine signaling. In addition, oxidative lipid damage and ferroptosis-associated signaling pathways may influence angiogenic regulation by modulating VEGF expression, endothelial activation, and vascular remodeling. This suggests that ferroptosis is not only a downstream consequence of oxidative stress but also an active contributor to placental vascular abnormalities [62, 63].
In this context, ferroptosis may represent a critical interface between metabolic stress and angiogenic dysregulation, integrating redox imbalance with structural and functional alterations in the placenta. However, current evidence is largely derived from experimental and observational studies, and further research is required to define its causal role and therapeutic potential in GDM [58].
Clinical implications and therapeutic perspectives
In a recent meta-analysis of 16 randomized controlled trials of 1173 women with GDM, Chatzakis et al., established that oxidative stress markers are significantly elevated in pregnant women with GDM compared to normoglycemic controls, with TAC being considerably lower and MDA, TOS, and other oxidative markers being elevated. Moreover, this meta-analysis demonstrated that supplementation with antioxidants, including selenium, vitamins, minerals, and omega-3 fatty acids can significantly reduce circulating MDA levels and increased TAC in women with GDM. Importantly, these redox improvements were accompanied by better glycemic control and reductions in inflammatory markers, indicating that oxidative imbalance in GDM is responsive to targeted nutritional intervention rather than being a fixed consequence of dysglycemia [64]. Another prospective study by Ruiz-Martínez et al., demonstrated that baseline oxidative stress markers are associated with incident postpartum hyperglycemia in the postpartum period. Specifically, basal MDA concentration, alongside pregestational BMI and HbA1c levels, were found to positively correlate with postpartum incident hyperglycemia in women with GDM, while higher antioxidant intake inversely correlated with this outcome [65]. Therefore, a study measuring plasma levels of thiol and disulfide molecules found that compensatory mechanisms of oxidative stress may be present in GDM and could be ameliorated through good glycemic regulation and antioxidant supplementation [66]. Jamilian et al., conducted a double-blind randomized controlled study in women with GDM, evaluating 1000 mg omega-3 fatty acids from flaxseed oil plus 400 IU vitamin E supplements (n = 30) or placebo (n = 30) for 6 weeks. Using biochemical assays to quantify oxidative and endothelial markers, they demonstrated significantly higher TAC and nitric oxide concentrations and lower MDA levels in the intervention group compared with placebo. Moreover, co-supplementation with omega-3 fatty acids and vitamin E showed no detectable changes in plasma glutathione and serum high-sensitivity C-reactive protein levels. Importantly, omega-3 fatty acids and vitamin E supplementation resulted in lower incidences of hyperbilirubinemia in newborns. These changes reflected improved systemic redox balance and endothelial function, providing direct experimental evidence that antioxidant therapy can modify core pathogenic pathways in GDM [67]. A subsequent randomized controlled trial by Zhang et al., examining various doses of vitamin D supplementation in 133 pregnant women with GDM found that high-dose vitamin D supplementation (50,000 IU every 2 weeks) resulted in significantly reduced fasting insulin levels and HOMA-IR, while elevating TAC and glutathione [68]. Thus, high-dose vitamin D supplementation significantly improved insulin resistance in pregnant women with GDM. Importantly, evidence from an overview of Cochrane Reviews indicated that vitamin D supplementation possibly reduced the risk of GDM, with a risk ratio of 0.51 (95% CI 0.27–0.97; low-quality evidence) [69]. Magnesium supplementation in the study performed by Maktabi et al., has also demonstrated consistent benefits for improving insulin sensitivity and modulating oxidative stress in women with GDM. A double-blind clinical trial examining magnesium-vitamin E co-supplementation (250 mg magnesium plus 400 mg vitamin E) revealed significant decreases in fasting plasma glucose and fasting plasma insulin in the treatment group, with elevated total antioxidant capacity increasing by 5.66 ± 0.86% [70]. Moreover, selenium supplementation during GDM demonstrated hypoglycemic and antioxidant properties in a prospective study of 180 pregnant Algerian women. Women receiving selenium (50 mg/day for 12 weeks starting from the second trimester) showed significant decline in fasting plasma glucose levels, alongside significant reinforcement of antioxidant enzyme activities including glutathione peroxidase, glutathione reductase, catalase, and superoxide dismutase, with simultaneous decreases in erythrocyte and plasma MDA. The beneficial effects appeared to be mediated through both antioxidant and insulin-mimetic properties of selenium, helping maintain blood glucose homeostasis and combat oxidative stress [71].
Conversely, myo-inositol represents one of the most rigorously studied nutritional interventions for GDM prevention and management. This naturally occurring compound participates in multiple signaling processes, including the pathways of insulin and gonadotropins, and has demonstrated consistent efficacy in reducing both GDM incidence and improving insulin sensitivity [72]. A comprehensive overview of Cochrane Reviews identified myo-inositol supplementation as a possible benefit intervention, with a risk ratio of 0.43 (95% CI 0.29–0.64; low-quality evidence) for GDM prevention, suggesting approximately 57% relative risk reduction [69]. Furthermore, research has documented that myo-inositol reduces inflammation and oxidative stress in human endothelial cells exposed to chronic hyperglycemia through multiple mechanisms, including decreased monocyte cell adhesion, reduced intracellular ROS production, and modulated inflammatory mediator expression [73]. The activation of the NF-κB signaling pathway by ROS leads to increased inflammatory responses and vascular injury in GDM [52]. Studies on fetal placental vessels revealed that metformin influences vascular responses in these tissues and may affect oxidative stress-related endothelial dysfunction, though the protective effects appear tissue-specific [74]. The emerging understanding of ferroptosis and neutrophil extracellular trap formation (NETosis) as regulated cell death pathways in GDM demonstrates that disturbances in iron metabolism and enhanced lipid peroxide formation contribute to placental dysfunction and systemic inflammation [75]. Furthermore, research has identified PGK1 as a key regulator of oxidative stress in GDM through the estradiol-Keap1-Nrf2 antioxidant pathway, suggesting that modulation of this pathway represents a novel therapeutic target for reducing oxidative stress-related pregnancy complications [76]. Despite growing evidence supporting the role of oxidative, inflammatory, and angiogenic biomarkers in GDM, their routine application in obstetric clinical practice remains limited. Most of these markers are not yet standardized, lack validated clinical thresholds, and have not been sufficiently evaluated in large prospective studies. Therefore, at present, they should be considered primarily as research tools rather than established clinical biomarkers.
Nevertheless, these data indicate that oxidative stress in GDM may not only be a central pathogenic mechanism but also a potential modifiable therapeutic target (Table 4). When integrated with standard metabolic management, antioxidant-based strategies may improve endothelial and placental function and potentially reduce the risk of adverse perinatal outcomes. However, existing trials remain limited in size and duration, underscoring the need for larger, adequately powered studies to define optimal formulations, timing of intervention, and long-term maternal and offspring benefits. Future research should therefore prioritize the integration of redox, inflammatory, and angiogenic biomarkers into longitudinal pregnancy cohorts, enabling stratification of GDM phenotypes based on placental biology rather than glycemia alone. Multi-omics approaches combining metabolomics, transcriptomics, and epigenetic profiling of placental tissue (as proposed by Samra et al. and Dias et al.) may identify molecular signatures predictive of vascular maladaptation. Such biologically informed stratification could facilitate personalized interventions targeting oxidative stress or endothelial dysfunction, moving GDM management beyond glucose-centered paradigms toward mechanism-based precision care. Collectively, future implementation in clinical practice will require standardization of assays, validation in diverse populations, and demonstration of added value beyond existing clinical risk models.
Table 4.
Antioxidant and nutraceutical interventions targeting oxidative stress in GDM
| Author (year) | Study design / population | Intervention (dose, duration) | Biomarkers assessed | Main outcomes | Clinical / mechanistic implication |
|---|---|---|---|---|---|
| Chatzakis et al., [64] | Network meta-analysis of 16 RCTs; n = 1173 women with GDM | Various antioxidants (selenium, vitamins, minerals, omega-3) | TAC, MDA, TOS, inflammatory and glycemic markers | GDM associated with ↓TAC and ↑MDA/TOS vs. controls; supplementation ↓MDA and ↑TAC; improved glycemia and inflammation | Oxidative imbalance in GDM is reversible and therapeutically targetable |
| Ruiz-Martínez et al., [65] | Prospective cohort in women with GDM | Dietary antioxidant intake (observational) | Baseline MDA; BMI; HbA1c | Basal MDA, BMI, HbA1c predicted postpartum hyperglycemia; higher antioxidant intake inversely associated | Oxidative stress predicts long-term dysglycemia; diet modulates risk |
| Erdoğan et al., [66] | Observational clinical study | Glycemic control ± antioxidants | Plasma thiol/disulfide balance | Evidence of compensatory redox mechanisms in GDM; improved with good glycemic control and antioxidants | Redox homeostasis is dynamic and responsive to intervention |
| Jamilian et al., [67] | Double-blind RCT; n = 60 women with GDM | Omega-3 (1000 mg/d) + Vit E (400 IU/d) for 6 weeks | TAC, MDA, NO, GSH, hs-CRP | ↑TAC, ↑NO, ↓MDA; no change in GSH/hs-CRP; ↓ neonatal hyperbilirubinemia | Improved redox balance and endothelial function; neonatal benefit |
| Zhang et al., [68] | RCT; n = 133 women with GDM | Vitamin D (50,000 IU every 2 weeks) | Fasting insulin, HOMA-IR, TAC, GSH | High-dose Vit D ↓ insulin & HOMA-IR; ↑TAC & GSH | Vitamin D improves insulin resistance and antioxidant status |
| Griffith et al., [69] | Overview of Cochrane Reviews | Vitamin D; myo-inositol | GDM incidence | Vitamin D RR 0.51; myo-inositol RR 0.43 for GDM prevention (low-quality evidence) | Nutraceuticals may reduce GDM risk |
| Maktabi et al., [70] | Double-blind RCT in GDM | Magnesium (250 mg/d) + Vit E (400 mg/d) | FPG, insulin, TAC | ↓FPG and insulin; ↑TAC (+ 5.66%) | Improved insulin sensitivity and antioxidant capacity |
| Saifi et al., [71] | Prospective study; n = 180 pregnant women | Selenium (50 mg/d for 12 weeks) | FPG; GPx, GR, CAT, SOD; MDA | ↓FPG; ↑antioxidant enzymes; ↓plasma/erythrocyte MDA | Selenium exerts insulin-mimetic and antioxidant effects |
| Mashayekh-Amiri et al., [72] | Systematic review/meta-analysis | Myo-inositol | GDM incidence; insulin sensitivity | Consistent reduction in GDM risk and improved insulin sensitivity | Myo-inositol is an effective metabolic modulator |
| Baldassarre et al., [73] | In vitro (human endothelial cells) | Myo-inositol under hyperglycemia | ROS, monocyte adhesion, inflammatory mediators | ↓ROS; ↓adhesion; ↓inflammation | Direct endothelial protection under hyperglycemia |
| Tarry-Adkins et al., [74] | Ex vivo placental vessels | Metformin | Vascular responses; oxidative stress | Tissue-specific modulation of endothelial function | Pharmacologic redox modulation is placenta-specific |
| Katsi et al., [75] | Mechanistic/clinical studies | — (ferroptosis, NETosis) | Lipid peroxides; iron metabolism | Ferroptosis and NETosis contribute to placental injury | New oxidative death pathways in GDM |
| Peng et al., [76] | Molecular/experimental | Estradiol–PGK1–Keap1–Nrf2 axis | Nrf2 signaling; ROS | PGK1 regulates antioxidant defense | Novel therapeutic target for redox control |
GDM gestational diabetes mellitus, RCT randomized controlled trial, TAC total antioxidant capacity, MDA malondialdehyde, TOS total oxidant status, FPG fasting plasma glucose, NO nitric oxide, GSH glutathione, hs-CRP high-sensitivity C-reactive protein, HOMA-IR homeostasis model assessment of insulin resistance; BMI – body mass index, GPx glutathione peroxidase, GR glutathione reductase, CAT catalase, SOD superoxide dismutase, ROS reactive oxygen species, RR risk ratio, NETosis neutrophil extracellular trap formation, Nrf2 nuclear factor erythroid 2–related factor 2, Keap1 Kelch-like ECH-associated protein 1, PGK1 phosphoglycerate kinase 1
Limitations
This review has several limitations that should be acknowledged. First, as a narrative review, it does not include a formal systematic search strategy, quantitative synthesis, or risk-of-bias assessment, which may limit the strength of evidence integration. Although literature screening was performed with methodological rigor, selection bias cannot be fully excluded. Second, grey literature was not systematically searched or included, which may have resulted in the omission of emerging or unpublished findings. Third, many of the biomarkers discussed are derived from experimental or observational studies and lack robust validation in large prospective clinical cohorts, limiting their immediate applicability in clinical practice. Currently, only a limited number of prospective cohort studies have evaluated these biomarkers in relation to clinically relevant outcomes in GDM, which restricts their translation into routine practice. Finally, the distinction between causal and adaptive mechanisms, particularly in the context of angiogenesis and oxidative stress, remains challenging due to the predominance of cross-sectional and mechanistic studies.
Conclusions
The evidence synthesized in this review demonstrates that maternal hyperglycemia initiates a redox–inflammatory cascade within the maternal–fetal interface, characterized by excessive ROS generation, NF-κB–driven cytokine activation, endothelial dysfunction, and profound dysregulation of angiogenic signaling. These molecular perturbations translate into the characteristic placental phenotype of GDM—hypervascularization composed of structurally immature microvessels, impaired endothelial responsiveness, and altered growth-factor receptor balance. Genetic studies establish that the core susceptibility to GDM is rooted in loci governing insulin secretion and glucose homeostasis, whereas placental pathology develops downstream of this inherited metabolic stress. However, variation in antioxidant, inflammatory, and angiogenic pathways, including genes such as IL6 and VEGF, modulates how maternal hyperglycemia is transduced into oxidative injury and vascular remodeling. Epigenetic mechanisms further amplify this process. Dysregulated miRNA networks and widespread DNA methylation changes in placental and fetal tissues integrate genetic background with environmental exposures such as obesity, nutrition, and oxidative burden, embedding metabolic stress into long-lasting alterations in gene regulation, angiogenesis, and immune signaling. These processes provide a mechanistic framework for fetal programming and the intergenerational transmission of cardiometabolic risk. Importantly, oxidative stress in GDM emerges not only as a central pathogenic mechanism but also as a modifiable therapeutic target. Randomized trials and meta-analyses demonstrate that antioxidant-oriented interventions—nutritional, dietary, and micronutrient-based—can improve redox balance, inflammatory tone, and insulin sensitivity. These data support a shift from a purely glycemia-centered paradigm toward a biologically informed approach that incorporates redox and vascular biology into GDM management. Future research should integrate oxidative, inflammatory, angiogenic, genetic, and epigenetic biomarkers into longitudinal pregnancy cohorts. Multi-omics profiling of placental tissue and maternal biofluids may enable stratification of GDM into biologically distinct endotypes, identifying women in whom endothelial dysfunction and oxidative injury dominate the disease trajectory. Such biologically informed stratification has the potential to transform GDM management from a glucose-centered approach into a precision framework targeting placental oxidative and vascular stress.
Author contributions
Conceptualization, A.B.; methodology, A.B. and M.Sz; software, A.B. and M.K; validation, A.B. and M.K; formal analysis, A.B.; investigation, A.B.; resources, AB.; data curation, A.B.; writing—original draft preparation, A.B.; writing—review and editing, A.J.K and M.Sz.; visualization, A.B.; supervision, A.B., M.Sz and A.J.K.; project administration, A.B.; funding acquisition, M.Sz. All authors have read and agreed to the published version of the manuscript.
Funding
The study was supported by the funds of the internal financing of Medical University of Bialystok (B.SUB.24.586).
Data availability
Not applicable.
Declarations
Competing interests
The authors declare no competing interests.
Conflict of interest
The authors declare no conflicts of interest.
Institutional review board
Not applicable.
Consent to publish
Not applicable.
Clinical trial number
Not applicable.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Kautzky-Willer A, Harreiter J, Bancher-Todesca D, Berger A, Repa A, Lechleitner M, Weitgasser R. [Gestational diabetes mellitus]. Wiener klinische Wochenschrift. 2016;128(Suppl 2):103–12. 10.1007/S00508-015-0941-1. [DOI] [PubMed] [Google Scholar]
- 2.Basri NI, Mahdy ZA, Ahmad S, Abdul Karim AK, Shan LP, Manaf A, M. R., Ismail NAM. The World Health Organization (WHO) versus the International Association of Diabetes and Pregnancy Study Group (IADPSG) diagnostic criteria of gestational diabetes mellitus (GDM) and their associated maternal and neonatal outcomes. Horm Mol Biol Clin Investig. 2018;34(1). 10.1515/hmbci-2017-0077. [DOI] [PubMed]
- 3.Sibiak R, Iciek R, Gastolek K, Chudzynska E, Meek C, Wender-Ozegowska E. Ten-year national trends in the prevalence and outcomes of gestational diabetes mellitus in Poland: a population-based study. Pol Archives Intern Med. 2026. 10.20452/pamw.17202. [DOI] [PubMed] [Google Scholar]
- 4.Salmen B-M, Reurean-Pintilei D, Salmen T, Bohîlțea R-E. Exploring Continuous Glucose Monitoring in Gestational Diabetes: A Systematic Review. Life (Basel Switzerland). 2025;15(9). 10.3390/life15091369. [DOI] [PMC free article] [PubMed]
- 5.Colson A, Sonveaux P, Debiève F, Sferruzzi-Perri AN. Adaptations of the human placenta to hypoxia: opportunities for interventions in fetal growth restriction. Hum Reprod Update. 2021;27(3):531–69. 10.1093/humupd/dmaa053. [DOI] [PubMed] [Google Scholar]
- 6.Fujimaki A, Watanabe K, Mori T, Kimura C, Shinohara K, Wakatsuki A. Placental oxidative DNA damage and its repair in preeclamptic women with fetal growth restriction. Placenta. 2011;32(5):367–72. 10.1016/J.PLACENTA.2011.02.004. [DOI] [PubMed] [Google Scholar]
- 7.Biri A, Onan A, Devrim E, Babacan F, Kavutcu M, Durak I. Oxidant status in maternal and cord plasma and placental tissue in gestational diabetes. Placenta. 2006;27(2–3):327–32. 10.1016/J.PLACENTA.2005.01.002. [DOI] [PubMed] [Google Scholar]
- 8.Boldeanu L, Dijmărescu AL, Radu M, Siloşi CA, Popescu-Drigă MV, Poenariu IS, Siloşi I, Boldeanu MV, Novac MB, Novac LV. The role of mediating factors involved in angiogenesis during implantation. Rom J Morphol Embryol. 2020;61(3):665–72. 10.47162/RJME.61.3.04. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Etchegaray-Armijo K, Bustos-Arriagada E, Navarro-Rosenblatt D, Vera C, Garmendia ML, Sobrevia L, López-Alarcón C, Casanello P. Biomarkers of oxidative stress in maternal plasma, umbilical cord and placenta of patients with gestational diabetes: a systematic review and meta-analysis. Free Radic Biol Med. 2025;237:650–65. 10.1016/J.FREERADBIOMED.2025.06.007. [DOI] [PubMed] [Google Scholar]
- 10.Mandò C, Castiglioni S, Novielli C, Anelli GM, Serati A, Parisi F, Lubrano C, Zocchi M, Ottria R, Giovarelli M. Placental Bioenergetics and Antioxidant Homeostasis in Maternal Obesity and Gestational Diabetes. Antioxid (Basel Switzerland). 2024;13(7). 10.3390/antiox13070858. [DOI] [PMC free article] [PubMed]
- 11.Qiu C, Hevner K, Abetew D, Enquobahrie DA, Williams MA. Oxidative DNA damage in early pregnancy and risk of gestational diabetes mellitus: A pilot study. Clin Biochem. 2011;44(10–11):804–8. 10.1016/J.CLINBIOCHEM.2011.04.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Qiu C, Hevner K, Abetew D, Sedensky M, Philip M, Enquobahrie DA, Williams MA. Mitochondrial DNA copy number and oxidative DNA damage in placental tissues from gestational diabetes and control pregnancies: a pilot study. Clin Lab. 2013;59(5–6):655–60. 10.7754/CLIN.LAB.2012.120227. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Rancourt RC, Ott R, Ziska T, Schellong K, Melchior K, Henrich W, Plagemann A. Visceral adipose tissue inflammatory factors (TNF-alpha, SOCS3) in gestational diabetes (GDM): Epigenetics as a clue in GDM pathophysiology. Int J Mol Sci. 2020;21(2). 10.3390/ijms21020479. [DOI] [PMC free article] [PubMed]
- 14.Meng Q, Shao L, Luo X, Mu Y, Xu W, Gao L, Xu H, Cui Y. Expressions of VEGF-A and VEGFR-2 in placentae from GDM pregnancies. Reproductive Biology Endocrinol. 2016a;14(1). 10.1186/s12958-016-0191-8. [DOI] [PMC free article] [PubMed]
- 15.Ehlers E, Talton OO, Schust DJ, Schulz LC. Placental Structural Abnormalities in Gestational Diabetes and When They Develop: A Scoping Review. Placenta. 2021;116:58. 10.1016/J.PLACENTA.2021.04.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Ravi Teja K, kumar AS, Graduate P, professor A. ISSN 2347-954X (Print) Histopathological Study of Placenta in Gestational Diabetes in a Tertiary Care Hospital. Scholars J Appl Med Sci (SJAMS. 2017;5(11 C):4500–6. 10.36347/sjams.2017.v05i11.038. [DOI] [Google Scholar]
- 17.Yadav AK, Yadav S, Dande K, Singh V, Kumar I, Yadav R. Histo-Morphological Comparison of Placental Adaptations in Normal and Gestational Diabetes Mellitus Pregnancies and Their Impact on Neonatal Outcomes. J Pharm Bioallied Sci. 2025;17(Suppl 2):S1758. 10.4103/JPBS.JPBS_376_25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Sallam NA, Palmgren VAC, Singh RD, John CM, Thompson JA. Programming of vascular dysfunction in the intrauterine milieu of diabetic pregnancies. Int J Mol Sci. 2018;19(11). 10.3390/ijms19113665. [DOI] [PMC free article] [PubMed]
- 19.Brito Nunes C, Borges MC, Freathy RM, Lawlor DA, Qvigstad E, Evans DM, Moen GH. Understanding the Genetic Landscape of Gestational Diabetes: Insights into the Causes and Consequences of Elevated Glucose Levels in Pregnancy. Metabolites. 2024;14(9). 10.3390/METABO14090508. [DOI] [PMC free article] [PubMed]
- 20.Lizárraga D, Gómez-Gil B, García-Gasca T, Ávalos-Soriano A, Casarini L, Salazar-Oroz A, García-Gasca A. Gestational diabetes mellitus: genetic factors, epigenetic alterations, and microbial composition. Acta Diabetol. 2024;61(1):1–17. 10.1007/S00592-023-02176-Y. [DOI] [PubMed] [Google Scholar]
- 21.Jarmuzek P, Wielgos M, Bomba-Opon DA. Placental pathologic changes in gestational diabetes mellitus. Neuroendocrinol Lett. 2015;36(2):101–5. [PubMed] [Google Scholar]
- 22.Madazli R, Tuten A, Calay Z, Uzun H, Uludag S, Ocak V. The incidence of placental abnormalities, maternal and cord plasma malondialdehyde and vascular endothelial growth factor levels in women with gestational diabetes mellitus and nondiabetic controls. Gynecol Obstet Invest. 2008;65(4):227–32. 10.1159/000113045. [DOI] [PubMed] [Google Scholar]
- 23.Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JPA, Straus S, Thorlund K, Jansen JP, Mulrow C, Catala-Lopez F, Gotzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med. 2015;162(11):777–84. 10.7326/M14-2385. [DOI] [PubMed] [Google Scholar]
- 24.Liang HL, Ma SJ, Xiao YN, Tan HZ. Comparative efficacy and safety of oral antidiabetic drugs and insulin in treating gestational diabetes mellitus: An updated PRISMA-compliant network meta-analysis. Med (United States). 2017;96(38). 10.1097/MD.0000000000007939. [DOI] [PMC free article] [PubMed]
- 25.Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, Atkins D, Barbour V, Barrowman N, Berlin JA, Clark J, Clarke M, Cook D, D’Amico R, Deeks JJ, Devereaux PJ, Dickersin K, Egger M, Ernst E, Tugwell P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7). 10.1371/journal.pmed.1000097. [DOI] [PMC free article] [PubMed]
- 26.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, Moher D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372. 10.1136/BMJ.N71 [DOI] [PMC free article] [PubMed]
- 27.Cosson E. Diagnostic criteria for gestational diabetes mellitus. Diabetes Metab. 2010;36(6 Pt 2):538–48. 10.1016/J.DIABET.2010.11.007. [DOI] [PubMed] [Google Scholar]
- 28.Coustan DR, Lowe LP, Metzger BE, Dyer AR. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol. 2010;202(6):654e1. 10.1016/J.AJOG.2010.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Agarwal MM. Gestational diabetes mellitus: An update on the current international diagnostic criteria. World J Diabetes. 2015;6(6):782. 10.4239/WJD.V6.I6.782. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Cichocka E, Gumprecht J. Does the Change in the Diagnostic Criteria for Gestational Diabetes in Poland Affect Maternal and Fetal Complications? A Prospective Study. Med (Kaunas Lithuania). 2022;58(3). 10.3390/MEDICINA58030398. [DOI] [PMC free article] [PubMed]
- 31.Caughey AB, Turrentine M. ACOG Practice Bulletin 190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018;131(2):E49–64. 10.1097/AOG.0000000000002501. [DOI] [PubMed] [Google Scholar]
- 32.Classification and Diagnosis of Diabetes. Standards of Medical Care in Diabetes—2022. Diabetes Care. 2022;45:S17–38. 10.2337/DC22-S002. [DOI] [PubMed] [Google Scholar]
- 33.Hassan NR, Abdelaziz BM, Aboelroose A, Azab H, Aboelros SA. Association of genetic variants of TCF7L2 gene with gestational diabetes mellitus. Egypt J Immunol. 2025;32(2):80–91. 10.55133/EJI.320208. [DOI] [PubMed] [Google Scholar]
- 34.Papadopoulou A, Lynch KF, Shaat N, Håkansson R, Ivarsson SA, Berntorp K, Agardh CD, Lernmark Å. Gestational diabetes mellitus is associated with TCF7L2 gene polymorphisms independent of HLA-DQB1*0602 genotypes and islet cell autoantibodies. Diabet Medicine: J Br Diabet Association. 2011;28(9):1018. 10.1111/J.1464-5491.2011.03359.X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Diceglie C, Anelli GM, Martelli C, Serati A, Dico A, Lo, Lisso F, Parisi F, Novielli C, Paleari R, Cetin I, Ottobrini L, Mandò C. Placental Antioxidant Defenses and Autophagy-Related Genes in Maternal Obesity and Gestational Diabetes Mellitus. Nutrients. 2021;13(4):1303. 10.3390/NU13041303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Halvatsiotis P, Tsokaki T, Tsitsis V, Palaiodimou L, Tsivgoulis G, Tsangaris I, Panagiotou MO, Houhoula D. IL-6 Polymorphism as a Predisposing Genetic Factor for Gestational Diabetes or Preeclampsia Development in Pregnancy with Obesity in Relation to VEGF and VEGFF Receptor Gene Expression Modalities. Diagnostics (Basel Switzerland). 2024;14(11). 10.3390/DIAGNOSTICS14111206. [DOI] [PMC free article] [PubMed]
- 37.Dong Pping. Association of vascular endothelial growth factor expression and polymorphisms with the risk of gestational diabetes mellitus. J Clin Lab Anal. 2019;33(2). 10.1002/JCLA.22686. [DOI] [PMC free article] [PubMed]
- 38.Troncoso F, Acurio J, Herlitz K, Aguayo C, Bertoglia P, Guzman-Gutierrez E, Loyola M, Gonzalez M, Rezgaoui M, Desoye G, Escudero C. (2017). Gestational diabetes mellitus is associated with increased pro-migratory activation of vascular endothelial growth factor receptor 2 and reduced expression of vascular endothelial growth factor receptor 1. 12(8), e0182509. 10.1371/JOURNAL.PONE.0182509 [DOI] [PMC free article] [PubMed]
- 39.Wander PL, Boyko EJ, Hevner K, Parikh VJ, Tadesse MG, Sorensen TK, Williams MA, Enquobahrie DA. Circulating early- and mid-pregnancy microRNAs and risk of gestational diabetes. Diabetes Res Clin Pract. 2017;132:1–9. 10.1016/J.DIABRES.2017.07.024/ATTACHMENT/34F8D1FA-E2E6-4C23-9AEC-5F6D9868BBE6/MMC1.DOCX. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Trejo-Gonzalez NL, Palomar-Morales M, Baiza-Gutman LA, Diaz-Rosas G, Ortega-Camarillo C, Contreras-Ramos A. Circulating MicroRNAs Associated with Changes in the Placenta and Their Possible Role in the Fetus During Gestational Diabetes Mellitus: A Review. Metabolites. 2025;15(6):367. 10.3390/METABO15060367/S1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Canouil M, Khamis A, Keikkala E, Hummel S, Lobbens S, Bonnefond A, Delahaye F, Tzala E, Mustaniemi S, Vaarasmaki M, Jarvelin MR, Sebert S, Kajantie E, Froguel P, Andrew T. (2021). Epigenome-Wide Association Study Reveals Methylation Loci Associated With Offspring Gestational Diabetes Mellitus Exposure and Maternal Methylome. Diabetes Care, 44(9), 1992. 10.2337/DC20-2960 [DOI] [PMC free article] [PubMed]
- 42.Reichetzeder C, Putra D, Pfab SE, Slowinski T, Neuber T, Kleuser C, Hocher B Increased global placental DNA methylation levels are associated with gestational diabetes. Clin Epigenetics. 2016;8(1). . 10.1186/S13148-016-0247-9. [DOI] [PMC free article] [PubMed]
- 43.Chen F, Fei X, Zhu W, Zhang Z, Shen Y, Mao Y, Zhu Q, Xu J, Zhou W, Li M, Du J. Placental DNA methylation changes in gestational diabetes mellitus. Epigenetics. 2022;17(13):2109–21. 10.1080/15592294.2022.2110193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Lu S, Wang J, Kakongoma N, Hua W, Xu J, Wang Y, He S, Gu H, Shi J, Hu W. DNA methylation and expression profiles of placenta and umbilical cord blood reveal the characteristics of gestational diabetes mellitus patients and offspring. Clin Epigenetics. 2022;14(1). 10.1186/S13148-022-01289-5. [DOI] [PMC free article] [PubMed]
- 45.Awamleh Z, Butcher DT, Hanley A, Retnakaran R, Haertle L, Haaf T, Hamilton J, Weksberg R. Exposure to Gestational Diabetes Mellitus (GDM) alters DNA methylation in placenta and fetal cord blood. Diabetes Res Clin Pract. 2021;174. 10.1016/J.DIABRES.2021.108690. [DOI] [PubMed]
- 46.Rong C, Cui X, Chen J, Qian Y, Jia R, Hu Y. DNA methylation profiles in placenta and its association with gestational diabetes mellitus. Experimental Clin Endocrinol Diabetes: Official J German Soc Endocrinol [and] German Diabetes Association. 2015;123(5):282–8. 10.1055/S-0034-1398666. [DOI] [PubMed] [Google Scholar]
- 47.Lesseur C, Armstrong DA, Paquette AG, Li Z, Padbury JF, Marsit CJ. Maternal Obesity and Gestational Diabetes are Associated with Placental Leptin DNA Methylation. Am J Obstet Gynecol. 2014;211(6):654e1. 10.1016/J.AJOG.2014.06.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Nogues P, Dos Santos E, Jammes H, Berveiller P, Arnould L, Vialard F, Dieudonné MN. Maternal obesity influences expression and DNA methylation of the adiponectin and leptin systems in human third-trimester placenta. Clin Epigenetics. 2019;11(1). 10.1186/S13148-019-0612-6. [DOI] [PMC free article] [PubMed]
- 49.Basak S, Mallick R, Sree N, B., Duttaroy AK. Placental Epigenome Impacts Fetal Development: Effects of Maternal Nutrients and Gut Microbiota. Nutrients. 2024;16(12):1860. 10.3390/NU16121860. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Musa E, Salazar-Petres E, Arowolo A, Levitt N, Matjila M, Sferruzzi-Perri AN, Musa E, -Petres ES, Matjila M, -Perri AS, Physiol J, Sferruzzi A. Obesity and gestational diabetes independently and collectively induce specific effects on placental structure, inflammation and endocrine function in a cohort of South African women. J Physiol. 2023;601(7):1287–306. 10.1113/JP284139. [DOI] [PubMed] [Google Scholar]
- 51.Lappas M, Permezel M, Rice GE. Release of proinflammatory cytokines and 8-isoprostane from placenta, adipose tissue, and skeletal muscle from normal pregnant women and women with gestational diabetes mellitus. J Clin Endocrinol Metab. 2004;89(11):5627–33. 10.1210/JC.2003-032097. [DOI] [PubMed] [Google Scholar]
- 52.Saucedo R, Ortega-Camarillo C, Ferreira-Hermosillo A, Díaz-Velázquez MF, Meixueiro-Calderón C, Valencia-Ortega J. Role of oxidative stress and inflammation in gestational diabetes mellitus. Antioxid (Basel Switzerland). 2023;12(10). 10.3390/ANTIOX12101812. [DOI] [PMC free article] [PubMed]
- 53.Meng Q, Shao L, Luo X, Mu Y, Xu W, Gao L, Xu H, Cui Y. Expressions of VEGF-A and VEGFR-2 in placentae from GDM pregnancies. Reprod Biol Endocrinol RB&E. 2016;14(1):61 10.1186/s12958-016-0191-8 [DOI] [PMC free article] [PubMed]
- 54.Zhou J, Ni X, Huang X, Yao J, He Q, Wang K, Duan T. Potential Role of Hyperglycemia in Fetoplacental Endothelial Dysfunction in Gestational Diabetes Mellitus. Cell Physiol Biochemistry: Int J Experimental Cell Physiol Biochem Pharmacol. 2016;39(4):1317–28. 10.1159/000447836. [DOI] [PubMed] [Google Scholar]
- 55.Klid S, Algaba-Chueca F, Maymó-Masip E, Ballesteros M, Inglés M, Guarque A, Vilanova-Ricart N, Prats A, Kulovic-Sissawo A, Weiss E, Hiden U, Vendrell J, Fernández-Veledo S, Megía A. Impaired angiogenesis in gestational diabetes is linked to succinate/SUCNR1 axis dysregulation in late gestation. J Physiol. 2025. 10.1113/JP288010. [DOI] [PubMed] [Google Scholar]
- 56.Meng Q, Shao L, Luo X, Mu Y, Xu W, Gao L, Xu H, Cui Y. (2016c). Expressions of VEGF-A and VEGFR-2 in placentae from GDM pregnancies. Reproductive Biology and Endocrinology: RB&E, 14(1). 10.1186/S12958-016-0191-8 [DOI] [PMC free article] [PubMed]
- 57.Xu J, Zhou F, Wang X, Mo C. Role of ferroptosis in pregnancy related diseases and its therapeutic potential. Front Cell Dev Biology. 2023a;11:1083838. 10.3389/FCELL.2023.1083838. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Zhao Y, Gao Q, Li B, Wang Y, Wang Y. Ferroptosis and its potential role in gestational diabetes mellitus: updated evidence from pathogenesis to therapy. Front Endocrinol. 2023;14:1177547. 10.3389/FENDO.2023.1177547/FULL. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Gumilar KE, Priangga B, Lu CH, Dachlan EG, Tan M. Iron metabolism and ferroptosis: A pathway for understanding preeclampsia. Biomed Pharmacother. 2023;167:115565. 10.1016/J.BIOPHA.2023.115565. [DOI] [PubMed] [Google Scholar]
- 60.Beharier O, Kajiwara K, Sadovsky Y. Ferroptosis, trophoblast lipotoxic damage, and adverse pregnancy outcome. Placenta. 2021;108:32. 10.1016/J.PLACENTA.2021.03.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Xu Q, Zhu C, Li L, Li J, An Z, Tang C. The Role of Ferroptosis in Women’s Health and Diseases. MedComm. 2025;6(8):e70296. 10.1002/MCO2.70296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Shao Y, Zhang N, Xu T, Zhao M, Liu K. Ferroptosis in obstetrical and gynecological diseases: A mini review. Front Bioscience - Landmark. 2024;29(8). 10.31083/J.FBL2908282/. [DOI] [PubMed]
- 63.Xu J, Zhou F, Wang X, Mo C. (2023b). Role of ferroptosis in pregnancy related diseases and its therapeutic potential. Frontiers in Cell and Developmental Biology, 11. 10.3389/FCELL.2023.1083838 [DOI] [PMC free article] [PubMed]
- 64.Chatzakis C, Sotiriadis A, Tsakmaki E, Papagianni M, Paltoglou G, Dinas K, Mastorakos G. The effect of dietary supplements on oxidative stress in pregnant women with gestational diabetes mellitus: A network meta-analysis. Nutrients. 2021;13(7). 10.3390/NU13072284. [DOI] [PMC free article] [PubMed]
- 65.Ruiz-Martínez ML, Gómez-Díaz RA, González V, Ángeles Mejía AL, Mondragón González S, Díaz Flores R, Saldaña M, Espinoza RC, Ramírez-García LA, Díaz Velázquez MF, Wacher NH. Association of Oxidative Stress Markers with Incident Hyperglycemia in Gestational Diabetes Mellitus in an Educational Intervention. Nutrients. 2025;17(4):680. 10.3390/NU17040680. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Erdoğan F, Şenkal E, Özer ÖF, İpek İÖ, Altuntaş ŞL, Özde Ş. Oxidative stress in maternal milk and cord blood in gestational diabetes mellitus: a prospective study. São Paulo Med J. 2022;140(3):390. 10.1590/1516-3180.2021.0209.R1.25082021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Jamilian M, Hashemi Dizaji S, Bahmani F, Taghizadeh M, Memarzadeh MR, Karamali M, Akbari M, Asemi Z. A Randomized Controlled Clinical Trial Investigating the Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Biomarkers of Oxidative Stress, Inflammation and Pregnancy Outcomes in Gestational Diabetes. Can J Diabetes. 2017;41(2):143–9. 10.1016/J.JCJD.2016.09.004. [DOI] [PubMed] [Google Scholar]
- 68.Zhang Q, Cheng Y, He M, Li T, Ma Z, Cheng H. Effect of various doses of vitamin D supplementation on pregnant women with gestational diabetes mellitus: A randomized controlled trial. Experimental Therapeutic Med. 2016;12(3):1889. 10.3892/ETM.2016.3515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Griffith RJ, Alsweiler J, Moore AE, Brown S, Middleton P, Shepherd E, Crowther CA. Interventions to prevent women from developing gestational diabetes mellitus: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2020;2020(6):CD012394. 10.1002/14651858.CD012394.PUB3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Maktabi M, Jamilian M, Amirani E, Chamani M, Asemi Z. The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes. Lipids Health Dis. 2018;17(1). 10.1186/S12944-018-0814-5. [DOI] [PMC free article] [PubMed]
- 71.Saifi H, Mabrouk Y, Saifi R, Benabdelkader M, Saidi M. Influence of selenium supplementation on carbohydrate metabolism and oxidative stress in pregnant women with gestational diabetes mellitus. J Med Biochem. 2020;39(2):191. 10.2478/JOMB-2019-0034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Mashayekh-Amiri S, Mohammad-Alizadeh-Charandabi S, Abdolalipour S, Mirghafourvand M. Myo-inositol supplementation for prevention of gestational diabetes mellitus in overweight and obese pregnant women: a systematic review and meta-analysis. Diabetol Metab Syndr. 2022;14(1):93. 10.1186/S13098-022-00862-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Baldassarre MPA, Di Tomo P, Centorame G, Pandolfi A, Di Pietro N, Consoli A, Formoso G. Myoinositol reduces inflammation and oxidative stress in human endothelial cells exposed in vivo to chronic hyperglycemia. Nutrients. 2021;13(7). 10.3390/NU13072210. [DOI] [PMC free article] [PubMed]
- 74.Tarry-Adkins JL, Robinson IG, Reynolds RM, Aye ILMH, Charnock-Jones DS, Jenkins B, Koulmann A, Ozanne SE, Aiken CE. Impact of Metformin Treatment on Human Placental Energy Production and Oxidative Stress. Front Cell Dev Biology. 2022;10:935403. 10.3389/FCELL.2022.935403/FULL. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Katsi V, Alifragki A, Fragkiadakis K, Kopidakis N, Kallergis E, Zacharis E, Kampanieris E, Simantirakis E, Tsioufis K, Marketou M. The Emerging Roles of Ferroptosis and NETosis in Pregnancy Complications: Insights into Preeclampsia and Gestational Diabetes Mellitus. Curr Issues Mol Biol. 2025;47(9). 10.3390/CIMB47090685. [DOI] [PMC free article] [PubMed]
- 76.Peng Y, Zhao H, Chen J, Wang CC, Zhang T, Yeung TC, Ouyang H, Zhu J, Chen X, Li M, Hu H, Zhong M. PGK1 Regulates Oxidative Stress in Gestational Diabetes Mellitus through the Estradiol-Keap1-Nrf2 Pathway. Int J Biol Sci. 2025;21(12):5496–513. 10.7150/IJBS.113728. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable.
